Melanoma Expert Focuses on Finding the Next Best Therapy
Source: Onc Live, December 2022
Clinical trials demand extreme rigor. A mistake in trial design, like a bookkeeping error, can lead regulators to reject a potentially valuable drug. Many researchers dislike this intense focus on dotting i’s and crossing t’s. Omid Hamid, MD, enjoys the challenge.
“You have to do everything precisely. You have to be willing to have your clinic up for review. You have to continually be on your game,” Hamid said in an interview with OncologyLive®.
Hamid’s enthusiasm for clinical trials and his expertise in conducting them have made him a world-renowned phase 1 immunotherapeutic researcher. His career has been defined through a significant role in testing most of the medications that have revolutionized the treatment landscape for patients with malignant melanoma since 2011, when the immune checkpoint inhibitor (ICI) ipilimumab (Yervoy) and the BRAF inhibitor vemurafenib (Zelboraf) gained their initial FDA approvals in advanced-disease settings.